Skip to main content

Advertisement

SpringerLink
Log in

Difficult gout and new approaches for control of hyperuricemia in the allopurinol-allergic patient

  • Published:
Current Rheumatology Reports Aims and scope Submit manuscript

Abstract

A major obstacle to the treatment of hyperuricemia in patients allergic to allopurinol is the limited availability of suitable, equally effective, alternative, urate-lowering drugs. Conventional uricosuric drugs, including probenecid and sulfinpyrazone, are recommended for allopurinolintolerant patients with gout and “underexcretion” hyperuricemia who have normal renal function and no history of nephrolithiasis. Therapeutic options in those in whom traditional uricosuric drugs are contraindicated, ineffective, or poorly tolerated include slow oral desensitization to allopurinol and cautious administration of oxipurinol. Allopurinol desensitization is useful particularly in those who have failed other treatment modalities. If available (as in Europe, South Africa, and Japan), benzbromarone may be tried in patients with gout and mild-to-moderate renal insufficiency. Recombinant urate oxidase can be used in the short-term prophylaxis and treatment of chemotherapy-associated hyperuricemia in patients with lymphoproliferative and myeloproliferative disorders. Hyperuricemia and gout occur with increased frequency in cyclosporine-treated allograft transplant recipients. The management of gout in these patients is complicated by two main factors: cyclosporine-induced renal impairment, and interactions with medications used to preserve the allograft.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References and Recommended Reading

  1. Wallace SL, Singer, SZ: Therapy in gout. Rheum Dis Clin North Am 1988, 14:441–457.

    PubMed  CAS  Google Scholar 

  2. Fam AG: Gout in the elderly: clinical presentation and treatment. Drugs Aging 1998, 13:229–243. A comprehensive review outlining the management of gout.

    Article  PubMed  CAS  Google Scholar 

  3. Emmerson BT: The management of gout. N Engl J Med 1996, 334:445–451. A detailed overview of the treatment of gout.

    Article  PubMed  CAS  Google Scholar 

  4. Rundles RW: The development of allopurinol. Arch Intern Med 1985, 145:1492–1503.

    Article  PubMed  CAS  Google Scholar 

  5. McInnes GT, Lawson DH, Jick H: Acute adverse reactions attributed to allopurinol in hospitalized patients. Ann Rheum Dis 1981, 40:245–249.

    PubMed  CAS  Google Scholar 

  6. Hande KR, Noone RM, Stone WJ: Severe allopurinol toxicity. Description and guidelines for prevention in patients with renal insufficiency. Am J Med 1984, 76:47–56.

    Article  PubMed  CAS  Google Scholar 

  7. Singer JZ, Wallace SL: The allopurinol hypersensitivity syndrome: unnecessary morbidity and mortality. Arthritis Rheum 1986, 29:82–87.

    Article  PubMed  CAS  Google Scholar 

  8. Arellano F, Sacristan JA: Allopurinol hypersensitivity syndrome: a review. Ann Pharmacotherapy 1993, 27:337–343. A review of allopurinol hypersensitivity syndrome.

    CAS  Google Scholar 

  9. Chan SH, Tan T: HLA and allopurinol drug eruption. Dermatologica 1989, 179:32–33.

    Article  PubMed  CAS  Google Scholar 

  10. Melson RD: Familial hypersensitivity to allopurinol with subsequent desensitization [letter]. Rheumatology 1999, 38:1301.

    Article  Google Scholar 

  11. Emmerson BT, Hazelton RA, Frazer IH: Some adverse reactions to allopurinol may be mediated by lymphocyte reactivity to oxipurinol. Arthritis Rheum 1988, 31:436–440.

    Article  PubMed  CAS  Google Scholar 

  12. Braden GL, Warzynski MJ, Golightly M, Ballow M: Cellmediated immunity in allopurinol-induced hypersensitivity. Clin Immunol Immunopathol 1994, 70:145–151.

    Article  PubMed  CAS  Google Scholar 

  13. Mauri-Hellweg D, Bettens F, Mauri D, et al.: Activation of drug-specific CD4+ and CD8+ T cells in individuals allergic to sulfonamides, phenytoin and carbamazepine. J Immunol 1995, 155:462–472.

    PubMed  CAS  Google Scholar 

  14. Morel D, Guez S, Merville P, et al.: Recurrent renal failure associated with hypersensitivity to allopurinol. Nephrol Dial Transplant 1999:14:780–781.

    Article  PubMed  CAS  Google Scholar 

  15. Suzuki Y, Inagi R, Aono T, Yamanishi K, Shiohara T: Human herpesvirus 6 infection as a risk factor for the development of severe drug induced hypersensitivity syndrome. Arch Dermatol 1998, 134:1108–1112. The report suggests that reactivation of human herpesvirus 6 may play a role in the development of severe allopurinol hypersensitivity syndrome.

    Article  PubMed  CAS  Google Scholar 

  16. Halevy S, Cohen AD, Livni E: The diagnostic role of the in vitro drug-induced interferon-g release test in Stevens-Johnson syndrome. Internat J Dermatol 1999, 38:835–840. An interesting investigation suggesting that in vitro allopurinol-induced release of interferon-g from peripheral blood T-lymphocytes may be useful in the diagnosis of Stevens-Johnson syndrome and other sensitivity reactions to allopurinol.

    Article  CAS  Google Scholar 

  17. Bellamy N, Gilbert JR, Brooks PM, Emmerson BT, Campbell J: A survey of current prescribing practices of anti-inflammatory and urate lowering drugs in gouty arthritis in the Province of Ontario. J Rheumatol 1988, 15:1841–1847.

    PubMed  CAS  Google Scholar 

  18. Zell SC, Carmichael JM: Evaluation of allopurinol use in patients with gout. Am J Hosp Pharmacy 1989, 46:1813–1816.

    CAS  Google Scholar 

  19. Wortmann RL: Effective management of gout: an analogy. Am J Med 1998, 105:513–514. A practical approach to the treatment of gout.

    Article  PubMed  CAS  Google Scholar 

  20. Kovalchik III MT: Sulfinpyrazone induced uric acid urolithiasis with renal failure. Conn Med 1981, 45:423–424.

    PubMed  Google Scholar 

  21. Jones DP, Mahmoud H, Chesney RW: Tumor lysis syndrome: pathogenesis and management. Pediatr Nephrol 1995, 9:206–212.

    Article  PubMed  CAS  Google Scholar 

  22. Earll JM, Saavedra M: Oxypurinol therapy in allopurinolallergic patients. Am Fam Physician 1983, 28:147–148.

    PubMed  CAS  Google Scholar 

  23. Lockard O Jr, Harmon C, Nolph K, Irvin W: Allergic reaction to allopurinol with cross-reactivity to oxipurinol. Ann Intern Med 1976, 85:333–335.

    PubMed  Google Scholar 

  24. O’Duffy JD: Oxipurinol therapy in allopurinol-sensitive patients [abstract]. Arthritis Rheum 1993, 36(suppl):S159.

    Google Scholar 

  25. Elion GB: Drugs in the treatment of hyperuricemia. Adv Nephrol 1974, 3:51–57.

    CAS  Google Scholar 

  26. Chalmars RA, Kromer H, Scott JT, Watts RWE: A comparative study of the xanthine oxidase inhibitors allopurinol and oxipurinol in man. Clin Sci 1968, 35:353–362.

    Google Scholar 

  27. Walter-Sack I, de Vries JX, Ernst B, et al.: Uric acid lowering effect of oxipurinol sodium in hyperuricemia patients-therapeutic equivalence to allopurinol. J Rheumatol 1996, 23:498–501.

    PubMed  CAS  Google Scholar 

  28. Masera G, Jankovic M, Zurlo MG, et al.: Urate oxidase prophylaxis of uric acid-induced renal damage in childhood leukemia. J Pediatr 1982, 100:152–155.

    Article  PubMed  CAS  Google Scholar 

  29. Pui C-H, Relling MV, Lascombes F, et al.: Urate oxidase in prevention and treatment of hyperuricemia associated with lymphoid malignancies. Leukemia 1997, 11:1813–1816.

    Article  PubMed  CAS  Google Scholar 

  30. Rozenberg S, Koeger A-C, Bougeois P: Urate oxidase for gouty arthritis in cardiac transplant recipients [letter]. J Rheumatol 1993, 20:2171.

    PubMed  CAS  Google Scholar 

  31. Davis S, Park YK, Abuchowski A, Davis FF: Hypouricemic effect of polyethyleneglycol modified urate oxidase. Lancet 1981, 2:281–283.

    Article  PubMed  CAS  Google Scholar 

  32. Mahmoud HH, Leverger G, Patte C, Harvey E, Lascombes F: Advances in the management of malignancy-associated hyperuricemia. Br J Cancer 1998, 77(suppl:4):18–20. A preliminary investigation of a potent recombinant urate oxidase (uricase) used in the prophylaxis and treatment of chemotherapy-associated hyperuricemia in patients with leukemia, lymphoma and myeloma.

    PubMed  Google Scholar 

  33. Lee CC, Wu X, Gibbs RA, et al.: Generation of cDNA probes directed by amino acid sequence: cloning of urate oxidase. Science 1988, 239:1288–1291.

    Article  PubMed  CAS  Google Scholar 

  34. Chua CC, Greenberg ML, Viau AT, Nucci M, Brenckman WD Jr, Hershfield MS: Use of polyethylene glycol-modified uricase (PEG-uricase) to treat hyperuricemia in a patient with non-Hodgkin lymphoma. Ann Intern Med 1988, 109:114–117.

    PubMed  CAS  Google Scholar 

  35. Zurcher RM, Bock HA, Thiel G: Excellent uricosuric efficacy of benzbromarone in cyclosporine-A-treated renal transplant patients: a prospective study. Nephrol Dial Transplant 1994, 9:548–551.

    PubMed  CAS  Google Scholar 

  36. Grahame R, Simmonds HA, McBride MB, Marsh FP: How should we treat tophaceous gout in patients with allopurinol hypersensitivity? Adv Exp Med Biol 1998, 431:19–23.

    PubMed  CAS  Google Scholar 

  37. Perez-Ruiz F, Calabozo M, Fernandez-Lopez MJ, et al.: Treatment of chronic gout in patients with renal function impairment. An open, randomized, actively controlled study. JCR: J Clin Rheumatol 1999, 5:49–55. A reappraisal of benzbromarone in the treatment of chronic gout in patients with renal impairment.

    PubMed  CAS  Google Scholar 

  38. Perez-Ruiz, F, Alonzo-Ruiz A, Calabozo M, et al.: Efficacy of allopurinol and benzbromarone for the control of hyperuricemia. A pathogenic approach to the treatment of primary chronic gout. Ann Rheum Dis 1998, 57:545–549.

    PubMed  CAS  Google Scholar 

  39. Muller OF, Schall R, Groenewoud G, et al.: The effect of benzbromarone on allopurinol/oxipurinol kinetics in patients with gout. Eur J Clin Pharmacol 1993, 44:69–72.

    Article  PubMed  CAS  Google Scholar 

  40. Saris SD, Piraino AJ, Morgan JM, et al.: Uricosuric effects of CGS-12970, a new thromboxane synthase inhibitor. Clin Pharm Ther 1993, 54:65–9.

    Article  CAS  Google Scholar 

  41. Kanamaru M, Uematsu T, Nagashima S, et al.: Aldose reductase inhibitory and uricosuric activities of FK366 in healthy volunteers. J Clin Pharmacol 1993, 33:1122–1131.

    PubMed  CAS  Google Scholar 

  42. Oosterhuis B, Storm G, Cornelissen PJG, et al.: Dose-dependent uricosuric effect of ambroxol. Eur J Clin Pharmacol 1993, 44:237–241.

    Article  PubMed  CAS  Google Scholar 

  43. Fam AG, Lewtas, J, Stein J, Paton TW: Desensitization to allopurinol in patients with gout and cutaneous reactions. Am J Med 1992, 93:299–302. A preliminary study describing slow oral desensitization to allopurinol, using a schedule of grades doses, in a group of patients allergic to allopurinol who have gout and renal impairment.

    Article  PubMed  CAS  Google Scholar 

  44. Meyrier A: Desensitization in a patient with chronic renal disease and severe allergy to allopurinol [letter]. BMJ 1976, 2:458.

    PubMed  CAS  Google Scholar 

  45. Webster E, Panush RS: Allopurinol hypersensitivity in a patient with severe chronic tophaceous gout. Arthritis Rheum 1985, 28:707–709.

    Article  PubMed  CAS  Google Scholar 

  46. Northridge DB, Almack PM: Allopurinol desensitization. Br J Pharmaceut Pract 1986, 8:200.

    Google Scholar 

  47. Unsworth J, Black DR, D’Assis Fonseca AE, Beswick DT: Desensitization to allopurinol: a cautionary tale [letter]. Ann Rheum Dis 1987, 46:646.

    PubMed  CAS  Google Scholar 

  48. Kelsey SM, Stuthers GR, Beswick T, Blake DR: Desensitization to allopurinol [letter]. Ann Rheum Dis 1987, 46:84.

    PubMed  CAS  Google Scholar 

  49. Ridley MG, Mathews JA: Desensitization to allopurinol [letter]. Ann Rheum Dis 1987, 46:875.

    Article  PubMed  CAS  Google Scholar 

  50. Gillott TJ, Whallett A, Zaphiropoulos G: Oral desensitization in patients with chronic tophaceous gout and allopurinol hypersensitivity [letter]. Rheumatol (Oxford) 1999, 38:85–86.

    Article  CAS  Google Scholar 

  51. Walz-LeBlanc BAE, Reynolds WJ, MacFadden DK: Allopurinol sensitivity in a patient with chronic tophaceous gout: success of intravenous desensitization after failure of oral desensitization. Arthritis Rheum 1991, 34:1329–1331.

    Article  PubMed  CAS  Google Scholar 

  52. Tanna SB, Barnes JF, Seth SK: Desensitization to allopurinol in a patient with previous failed desensitization. Ann Pharmacother 1999, 33:1180–1183. An interesting case report of a patient with gouty arthritis and renal insufficiency who was successfully re-desensitized to allopurinol after initial failure.

    Article  PubMed  CAS  Google Scholar 

  53. Audicana M, Echechipia S, Fernandez E, Urrutia I: Desensitization in a case of fixed eruption from allopurinol [abstract]. Clin Exp Allergy 1990, 22:121.

    Google Scholar 

  54. Kelso JM, Keating RM: Successful desensitization for treatment of a fixed drug eruption to allopurinol. J Allergy Clin Immuno 1996, 97:1171–1172.

    Article  CAS  Google Scholar 

  55. Umpierrez A, Cuesta-Herranz J, De Las Heras M, Lluch-Bernal M, Figueredo E, Sastre J: Successful desensitization of a fixed drug eruption caused by allopurinol. J Allergy Clin Immunol 1998, 101:286–287. The case report describes a patient successfully desensitized to allopurinol-induced fixed drug eruption.

    Article  PubMed  CAS  Google Scholar 

  56. Dunne SM, Fam AG, Iazzetta J: Efficacy and safety of desensitization to allopurinol following cutaneous reactions [abstract]. Arthritis Rheum 1998, 41(suppl):S151.

    Google Scholar 

  57. Fam AG, Dunne SM, Iazzetta J, Paton TW: Efficacy and safety of desensitization to allopurinol following cutaneous reactions. Arthritis Rheum, in press. A retrospective analysis evaluating the outcome, safety, and long-term clinical utility of slow oral desensitization to allopurinol in a larger group of patients with gout and maculopapular eruptions to the drug. The study outlines the indications for allopurinol desensitization and proposed dosing guidelines.

  58. Ronjeau J-C, Stern RS: Severe adverse cutaneous reactions to drugs. New Engl J Med 1994, 331:1272–1285.

    Article  Google Scholar 

  59. Ronjeau J-C, Kelly JP, Naldi L, et al.: Medication use and the risk of Stevens-Johnson syndrome or toxic epidermal necrolysis. New Engl J Med 1995, 333:1600–1607.

    Article  Google Scholar 

  60. Lin H-Y, Rocher LL, McQuillan MA, Schmaltz S, Palella TD, Fox IH: Cyclosporine-induced hyperuricemia and gout. N Engl J Med 1989, 321:287–292. A detailed investigation of the mechanisms of cyclosporineinduced hyperuricemia.

    Article  PubMed  CAS  Google Scholar 

  61. Burack DA, Griffith BP, Thompson ME, Kahl LE: Hyperuricemia and gout among heart transplant recipients receiving cyclosporine. Am J Med 1992, 92:141–146.

    Article  PubMed  CAS  Google Scholar 

  62. Clive DM: Renal transplant-associated hyperuricemia and gout. J Am Soc Nephrol 2000, 11:974–979. A comprehensive review of cyclosporine-associated hyperuricemia and gout in renal transplant patients.

    PubMed  CAS  Google Scholar 

  63. Marcen R, Gallego N, Orofino L, et al.: Impairment of tubular secretion of urate in renal transplant patients on cyclosporine. Nephron 1995, 70:307–313.

    PubMed  CAS  Google Scholar 

  64. Laine J, Holmberg C: Mechanisms of hyperuricemia in cyclosporine-treated renal transplanted children. Nephron 1996, 74:318–323.

    Article  PubMed  CAS  Google Scholar 

  65. Shahinfar S, Simpson RL, Carides AD, et al.: Safety of losartan in hypertensive patients with thiazide-induced hyperuricemia. Kidney International 1999, 56:1879–1885. A study of the uricosuric effects of losartan in hypertensive patients with thiazide-induced hyperuricemia.

    Article  PubMed  CAS  Google Scholar 

  66. Minghelli G, Seydoux C, Goy J-J, Burnier M: Uricosuric effect of the angiotensin II receptor antagonist losartan in heart transplant recipients. Transplantation 1998, 66:268–271.

    Article  PubMed  CAS  Google Scholar 

  67. Boran M, Gonenc F, Cetin S: Losartan in renal allograft recipients receiving cyclosporine A [letter]. Nephron 1999, 83:93–94. A preliminary study examining the uricosuric effects of losartan in cyclosporine-treated renal transplant patients.

    Article  PubMed  CAS  Google Scholar 

  68. Puig JG, Mateos F, Buno A, et al.: Effect of eprosartan and losartan on uric acid metabolism in patients with essential hypertension. J Hypertension 1999, 17:1033–1039. The study investigates the effects of two angiotensin II receptor antagonists, losartan and eprosartan, on uric acid metabolism.

    Article  CAS  Google Scholar 

  69. Owens P, Kelly L, Nallen R, et al.: Comparison of antihypertensive and metabolic effects of losartan and losartan in combination with hydrochlorothiazide-a randomized controlled trial. J Hypertension 2000, 18:339–345. The report describes effects of losartan on serum urate levels in patients with hypertension, including those receiving concomitant hydrochlorothiazide.

    Article  CAS  Google Scholar 

  70. Yamamoto T, Moriwaki Y, Takahashi S, et al.: Effect of losartan potassium, an angiotensin II receptor antagonist, on renal excretion of oxipurinol and purine bases. J Rheumatol 2000, 27:2232–2236. A preliminary short-term study showing that single-dose coadministration of allopurinol and losartan increases the renal excretion of uric acid, xanthine, and oxipurinol.

    PubMed  CAS  Google Scholar 

  71. Jacobs F, Mamzer-Bruneel MF, Skhiri H, et al.: Safety of mycophenolate mofetil-allopurinol combination in kidney transplant recipients with gout [letter]. Transplantation 1997, 64:1087–1088.

    Article  PubMed  CAS  Google Scholar 

  72. Hilbrands LB, Hoitsma AJ, Wetzels JFM, Koene RAP: Detailed study of changes in renal function after conversion from cyclosporine to azathioprine. Clin Nephrol 1996, 45:230–235.

    PubMed  CAS  Google Scholar 

  73. Ochiai T, Ishibashi M, Fukao K, et al.: Japanese multicenter studies of FK506 in renal transplantation. Transplant Proc 1995, 27:50–53.

    PubMed  CAS  Google Scholar 

  74. Komoriya K, Osada Y, Hasegawa M, et al.: Hypouricemic effect of allopurinol and the novel xanthine oxidase inhibitor TEI-6729 in chimpanzees. Eur J Pharmacol 1993, 250:455–460.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Sunnybrook and Women’s College Health Sciences Centre, 2075 Bayview Avenue M-1402, M4M 3M5, Toronto, Ontario, Canada

    Adel G. Fam MD, FRCP(C)

Authors
  1. Adel G. Fam MD, FRCP(C)
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Fam, A.G. Difficult gout and new approaches for control of hyperuricemia in the allopurinol-allergic patient. Curr Rheumatol Rep 3, 29–35 (2001). https://doi.org/10.1007/s11926-001-0048-8

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11926-001-0048-8

Keywords

Search

Navigation